DOCSLIB.ORG

Suppressive Effects of Antiandrogens, Finasteride and Flutamide on Development of Prostatic Lesions in a Transgenic Rat Model

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Suppressive Effects of Antiandrogens, Finasteride and Flutamide on Development of Prostatic Lesions in a Transgenic Rat Model Prostate Cancer and Prostatic Diseases (2007) 10, 378–383 & 2007 Nature Publishing Group All rights reserved 1365-7852/07 $30.00 www.nature.com/pcan ORIGINAL ARTICLE Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model Y-M Cho1, S Takahashi, M Asamoto, S Suzuki, M Tang and T Shirai Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Japan Transgenic (TG) rats bearing a probasin promoter/simian virus 40 T antigen (SV40 Tag) construct were treated with antiandrogens to examine their ability to suppress prostate carcinogenesis. Finasteride and flutamide were administered to 10-week-old TG rats five times a week for 2, 5 and 7 weeks. Antiandrogen-treated prostates exhibited atrophic glandular structures with almost no expression of SV40 Tag and only weak signals for androgen receptors. Furthermore, quantitative data for ventral prostate adenocarcinomas showed significant decrease with antiandrogen treatment. Both finasteride and flutamide had the ability to suppress SV40 Tag-driven carcinogenesis through their different antiandrogenic mechanisms, suggesting that this TG model is suitable for exploring the potential of agents to inhibit prostate cancer development. Prostate Cancer and Prostatic Diseases (2007) 10, 378–383; doi:10.1038/sj.pcan.4500971; published online 24 April 2007 Keywords: chemoprevention; transgenic rat; finasteride; flutamide Introduction Approaches to influence androgen levels in prostatic tissue include (a) inhibition of the pituitary secretion of Among US men, prostate cancer is the most common luteinizing hormone (LH) by LH-releasing hormone non-cutaneous neoplasm and the second leading cause (LHRH) analogs, (b) prevention of the conversion of of cancer death. It has been estimated that there will be testosterone to dihydrotestosterone (DHT) by 5a-reduc- approximately 234 460 new cases of prostate cancer and tase in the prostate and (c) blocking prostatic androgen 27 350 associated deaths in the United States in 2006.1 receptors (ARs) using steroid-like antagonists with no Over 60% of these newly diagnosed cases of prostate intrinsic activity, to reduce potentially unacceptable cancer will be pathologically advanced; at this stage, systemic toxicity.6 One such agonist is the azasteroid there is no cure and the prognosis is dismal. Since the finasteride.7 Another potential suppressive agent is frequency of latent prostatic tumors has been shown to the nonsteroidal antiandrogen flutamide, which exerts increase with each decade of life from the 50s (5.3–14%) to effects by interfering with the binding of DHT or the 90s (40–80%)2 and relatively long time periods are testosterone to the AR.5 necessary for progression to actual prostate cancer, the The study of prostate cancer chemoprevention and concept of chemoprevention has attracted much attention. treatment has been hindered by the lack of appropriate The majority of prostate cancers initially respond to animal models. Recently, we have established transgenic androgen ablation therapy because of hormone-depen- (TG) rats, designated TRAP (Transgenic Rat for Adeno- dent growth,3 but relapse with generation of hormone- carcinoma of the Prostate), bearing a probasin promoter/ independent cancer cell occurs and eventually leads to a simian virus 40 T antigen (SV40 Tag) construct in which fatal outcome in many cases.4,5 Although androgen androgen-dependent prostate cancers develop rapidly.8–10 ablation at this hormone refractory stage is ineffective, In our TRAP model, high-grade prostatic intraepithe- androgen deprivation strategy as an early intervention lial neoplasia (PINs) are found from 4 weeks of age, and may delay the promotion and/or progression of prostate prostate adenocarcinomas in the ventral, dorsolateral cancer, resulting in reduced morbidity and mortality. and anterior lobes are observed at 100% incidences before 15 weeks of age. Prostate adenocarcinomas Correspondence: Dr S Takahashi, Department of Experimental developing in TRAP are strictly androgen dependent in Pathology and Tumor Biology, Nagoya City University Graduate a pattern similar to that of human primary prostate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, cancer. TRAP lesions have many advantages, for Nagoya 467-8601, Japan. example, their large size allows adequate materials to E-mail: [email protected] be obtained and development of prostate cancer occurs 1Current address: Division of Pathology, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan in a shorter experimental period and more efficiently Received 20 December 2006; revised and accepted 26 March 2007; compared with several other rat prostate carcinogenesis 11–19 published online 24 April 2007 models. These characteristics of TRAP may make it Suppressive effects of antiandrogens, finasteride and flutamide Y-M Cho et al particularly suitable for evaluation of strategies for were demonstrated with diaminobenzidine as the 379 chemoprevention and treatment. The present study was substrate. conducted to assess whether finasteride and flutamide have the ability to suppress prostate carcinogenesis in our TRAP model. Statistical analysis Statistical analysis of differences between means and incidences was carried out using analysis of variance and Materials and methods the Kruskal–Wallis test, respectively. When positive results were obtained, the Mann–Whitney U-test with Animal and treatment Bonferroni correction was applied to evaluate the Male heterozygous TRAP rats established in our labora- statistical significance between treatment groups. tory with a Sprague–Dawley genetic background were used in the present study.8,9 They were housed three/ cage on wood-chip bedding in an air-conditioned animal Results room at 23721C and 50710% humidity, with food (Oriental MF, Oriental Yeast Co., Tokyo, Japan) and tap TRAP rats treated with finasteride or the high dose of water available ad libitum. Finasteride (Merck KGaA, flutamide for 5 and 7 weeks showed significantly Darmstadt, Germany) and flutamide (Nippon Kayaku (Po0.001) lower prostate weights relative to body Co. Ltd, Tokyo, Japan) were suspended in 0.5% methyl- weights as compared to controls (Table 1). Macroscopi- cellulose 400 cP (Wako Pure Chemical Industries Ltd, cally, prostates of TRAP in the non-treated group showed Osaka, Japan) and administrated to 10-week-old TG rats slight enlargement and irregular surfaces but no appar- five times a week via intragastric route at concentrations ent nodule or mass formation. In contrast, antiandrogen of 10 and 5 or 20 mg/kg, respectively. Animals were treatment was associated with obvious prostate and then killed at weeks 2, 5 and 7, and lesions in the prostate seminal vesicle atrophy. Histopathological findings for were histopathologically classified as described pre- prostatic lesions are summarized in Table 2. Antiandro- viously into PIN and adenocarcinoma categories.8 The gen treatment for 2 weeks caused destruction of areas of lesions in each prostate sample were quantita- glandular structure with inflammatory cell infiltration tively measured with an Image Processor for Analytical (Figure 1a). After treatment for 7 weeks, atrophic glands Pathology (Sumika Technos Co., Osaka). Testosterone were frequently observed with minimal nuclear atypia levels in serum were also analyzed by radioimmuno- (Figures 1b and 2). PINs and/or adenocarcinomas were assay at a commercial laboratory (SRL, Tokyo). detected in all lobes. There were no statistically sig- The present experiment was performed under proto- nificant differences in the incidences of PINs or cols approved by the Institutional Animal Care and Use adenocarcinomas among the groups. However, the areas Committee of Nagoya City University Graduate School of lesions were significantly reduced in finasteride- and of Medical Sciences. high dose of flutamide-treated groups in the ventral and lateral lobes, but not the dorsal lobe. The lesions also tended to be suppressed without significance by low- Immunohistochemistry analysis dose flutamide in all lobes (Table 3). The avidin–biotin–peroxidase complex (ABC) method Almost no expression of the SV40 Tag and only weak was used to determine the expression of the SV40 signals for AR were detected in involuted glands of rats Tag and the AR in prostate epithelial cells. Prostate treated with antiandrogens (Figure 3). Serum testoster- sections were treated with mouse anti-SV40 Tag (1:250, one levels were not influenced by finasteride treatment. Pharmingen, San Diego, CA, USA), or rabbit anti-AR On the other hand, the levels of testosterone were (1:200, Affinity Bioreagents, Golden, CO, USA) and significantly (Po0.001) increased in the flutamide-trea- then sequentially with secondary antibody and ABC ted groups in a dose-dependent manner at week 5. At (Vectastain ABC Elite kit, Vector Laboratories, week 7, however, levels had returned to normal level Burlingame, CA, USA). The sites of peroxidase binding (Figure 4). Table 1 Relative prostate weights in TRAP rats treated with finasteride or flutamide for 5 and 7 weeks Duration Treatment No. of rats Final body weight (g) Relative prostate weight (%) Dorsolateral lobe Anterior lobe and seminal vesicles 5 weeks Finasteride 10 mg/kg 5 429.4715.9 0.1570.02 0.2470.03*** Flutamide 20 mg/kg 5 397.7753.2 0.1170.02** 0.2170.07*** Flutamide 5 mg/kg 5 424.8743.5 0.1570.02 0.3570.05* Control 5 407.8756.1
Load more

Recommended publications
  • Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’S Time to Sound the Alarm
    Review Article Health promotion, disease prevention, and lifestyle pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health 2020 Jul 38(3): 323-337 https://doi.org/10.5534/wjmh.200012 Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It’s Time to Sound the Alarm Abdulmaged M. Traish Department of Urology, Boston University School of Medicine, Boston, MA, USA 5α-dihydrotestosterone (5α-DHT) is the most potent natural androgen. 5α-DHT elicits a multitude of physiological actions, in a host of tissues, including prostate, seminal vesicles, hair follicles, skin, kidney, and lacrimal and meibomian glands. How- ever, the physiological role of 5α-DHT in human physiology, remains questionable and, at best, poorly appreciated. Recent emerging literature supports a role for 5α-DHT in the physiological function of liver, pancreatic β-cell function and survival, ocular function and prevention of dry eye disease and kidney physiological function. Thus, inhibition of 5α-reductases with finasteride or dutasteride to reduce 5α-DHT biosynthesis in the course of treatment of benign prostatic hyperplasia (BPH) or male pattern hair loss, known as androgenetic alopecia (AGA) my induces a novel form of tissue specific androgen deficien- cy and contributes to a host of pathophysiological conditions, that are yet to be fully recognized. Here, we advance the con- cept that blockade of 5α-reductases by finasteride or dutasteride in a mechanism-based, irreversible, inhabitation of 5α-DHT biosynthesis results in a novel state of androgen deficiency, independent of circulating testosterone levels. Finasteride and dutasteride are frequently prescribed for long-term treatment of lower urinary tract symptoms in men with BPH and in men with AGA.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Finasteride Adverse Effects and Post-Finasteride Syndrome
    Journal of Mind and Medical Sciences Volume 3 | Issue 1 Article 9 2016 Finasteride adverse effects and post-finasteride syndrome; implications for dentists Stana Paunica Carol Davila University, Faculty of Dental Medicine, Department of Periodontology, [email protected] Marina Giurgiu Carol Davila University, Faculty of Dental Medicine, Department of Periodontology Andrei Vasilache Carol Davila University, Faculty of Dental Medicine, Department of Periodontology Ioana Paunica Carol Davila University, Faculty of General Medicine Ion Motofei Carol Davila University, Faculty of General Medicine See next page for additional authors Follow this and additional works at: http://scholar.valpo.edu/jmms Part of the Oral Biology and Oral Pathology Commons, and the Periodontics and Periodontology Commons Recommended Citation Paunica, Stana; Giurgiu, Marina; Vasilache, Andrei; Paunica, Ioana; Motofei, Ion; Vasilache, Adriana; Dumitriu, Horia Traian; and Dumitriu, Anca Silvia (2016) "Finasteride adverse effects and post-finasteride syndrome; implications for dentists," Journal of Mind and Medical Sciences: Vol. 3 : Iss. 1 , Article 9. Available at: http://scholar.valpo.edu/jmms/vol3/iss1/9 This Research Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at [email protected]. Finasteride adverse effects and post-finasteride syndrome; implications for dentists Authors Stana Paunica, Marina Giurgiu, Andrei Vasilache, Ioana Paunica, Ion Motofei, Adriana Vasilache, Horia Traian Dumitriu, and Anca Silvia Dumitriu This research article is available in Journal of Mind and Medical Sciences: http://scholar.valpo.edu/jmms/vol3/iss1/9 J Mind Med Sci.
    [Show full text]
  • Gender-Affirming Hormone Therapy
    GENDER-AFFIRMING HORMONE THERAPY Julie Thompson, PA-C Medical Director of Trans Health, Fenway Health March 2020 fenwayhealth.org GOALS AND OBJECTIVES 1. Review process of initiating hormone therapy through the informed consent model 2. Provide an overview of masculinizing and feminizing hormone therapy 3. Review realistic expectations and benefits of hormone therapy vs their associated risks 4. Discuss recommendations for monitoring fenwayhealth.org PROTOCOLS AND STANDARDS OF CARE fenwayhealth.org WPATH STANDARDS OF CARE, 2011 The criteria for hormone therapy are as follows: 1. Well-documented, persistent (at least 6mo) gender dysphoria 2. Capacity to make a fully informed decision and to consent for treatment 3. Age of majority in a given country 4. If significant medical or mental health concerns are present, they must be reasonably well controlled fenwayhealth.org INFORMED CONSENT MODEL ▪ Requires healthcare provider to ▪ Effectively communicate benefits, risks and alternatives of treatment to patient ▪ Assess that the patient is able to understand and consent to the treatment ▪ Informed consent model does not preclude mental health care! ▪ Recognizes that prescribing decision ultimately rests with clinical judgment of provider working together with the patient ▪ Recognizes patient autonomy and empowers self-agency ▪ Decreases barriers to medically necessary care fenwayhealth.org INITIAL VISITS ▪ Review history of gender experience and patient’s goals ▪ Document prior hormone use ▪ Assess appropriateness for gender affirming medical
    [Show full text]
  • Androgenic Alopecia; the Risk–Benefit Ar Tio of Finasteride David L
    Journal of Mind and Medical Sciences Volume 5 | Issue 1 Article 2 2018 Androgenic alopecia; the risk–benefit ar tio of Finasteride David L. Rowland Valparaiso University, Department of Psychology, Valparaiso, [email protected] Ion G. Motofei Carol Davila University of Medicine and Pharmacy, Faculty of General Medicine, [email protected] Ioana Păunică Carol Davila University of Medicine and Pharmacy, Faculty of General Medicine Petrișor Banu Carol Davila University of Medicine and Pharmacy, Faculty of General Medicine Mihaela F. Nistor Carol Davila University of Medicine and Pharmacy, Faculty of General Medicine See next page for additional authors Follow this and additional works at: https://scholar.valpo.edu/jmms Part of the Dermatology Commons, Endocrine System Diseases Commons, Integrative Medicine Commons, and the Skin and Connective Tissue Diseases Commons Recommended Citation Rowland, David L.; Motofei, Ion G.; Păunică, Ioana; Banu, Petrișor; Nistor, Mihaela F.; Păunică, Stana; and Constantin, Vlad D. (2018) "Androgenic alopecia; the risk–benefit ar tio of Finasteride," Journal of Mind and Medical Sciences: Vol. 5 : Iss. 1 , Article 2. DOI: 10.22543/7674.51.P16 Available at: https://scholar.valpo.edu/jmms/vol5/iss1/2 This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at [email protected]. Androgenic alopecia; the risk–benefit ar tio of Finasteride Authors David L. Rowland, Ion G. Motofei, Ioana Păunică, Petrișor Banu, Mihaela F. Nistor, Stana Păunică, and Vlad D.
    [Show full text]
  • Risk of Depression After 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
    Original Article Prostate and male voiding dysfunctions pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health Published online May 23, 2019 https://doi.org/10.5534/wjmh.190046 Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis Jae Heon Kim1,2 , Sung Ryul Shim3,4 , Yash Khandwala1 , Francesco Del Giudice5 , Simon Sorensen6 , Benjamin I. Chung1 1Department of Urology, Stanford University Medical Center, Stanford, CA, USA, 2Department of Urology and 3Urological Biomedicine Research Institute, Soonchunhyang University Seoul Hospital, Soon Chun Hyang University College of Medicine, Seoul, 4Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea, 5Department of Urology, Sapienza University of Rome, Rome, Italy, 6Department of Urology, Aarhus University Hospital, Aarhus, Denmark Purpose: Although five-alpha reductase inhibitor (5-ARI) is one of standard treatment for benign prostatic hyperplasia (BPH) or alopecia, potential complications after 5-ARI have been issues recently. This study aimed to investigate the risk of depres- sion after taking 5-ARI and to quantify the risk using meta-analysis. Materials and Methods: A total of 209,940 patients including 207,798 in 5-ARI treatment groups and 110,118 in control groups from five studies were included for final analysis. Inclusion criteria for finial analysis incudes clinical outcomes re- garding depression risk in BPH or alopecia patients. Overall hazard ratio (HR) and odds ratio (OR) for depression were ana- lyzed. Moderator analysis and sensitivity analysis were performed to determine whether HR or OR could be affected by any variables, including number of patients, age, study type, and control type. Results: The pooled overall HRs for the 5-ARI medication was 1.23 (95% confidence interval [CI], 0.99–1.54) in a random effects model.
    [Show full text]
  • Investigation About the Effects and the Detection of Finasteride, a Substance Which Can Be Misused As Masking Agent in Doping Control” W
    PROJECT SUMMARY “Investigation about the effects and the detection of finasteride, a substance which can be misused as masking agent in doping control” W. Schanzer, H. Geyer (German Sport University, Cologne, Germany) Finasteride is an inhibitor of 5-alpha reductase, the enzyme responsible for conversion of testosterone to dihydrotestosterone. It is administered orally in a dose of 5 mg daily for the treatment of benign prostatic hypertrophy. Since 1999 it is also admitted in several countries for the treatment of men with hair loss (androgenetic alopecia) and it seems to become a so called ,,life style drug”. The recommended dose for the treatment of hair loss is 1 mglday. Recent studies with finasteride have shown, that this substance can be misused as a potential masking agent. The application of finasteride may prevent the detection of misuse of anabolic-androgenic steroids like nandrolone, norandrostendione, norandrostenediols, dihydrotestosterone and testosterone. These preliminary results should be confirmed by more extensive studies with several volunteers. If the preliminary results can be confirmed, it should be discussed, if finasteride is added to the prohibited class of masking agents. The second aim of the study is to develop and validate a sensitive and specific method for the detection of finasteride misuse. Investigation about the effects and the detection of finasteride, a substance which can be misused as masking agent in doping control Results and conclusions Finasteride is an inhibitor of 5-alpha reductase and used for the treatment of benign prostatic hypertrophy and androgenetic alopecia. Investigations with finsteride with only one volunteer have shown, that the use of finasteride complicates the detection of the misuse of several anabolic steroids in doping control.
    [Show full text]
  • And Prostatic Acid Phosphatase (PAP) in Men with Benign Prostatic Hyperplasia (BPH)
    Prostate Cancer and Prostatic Diseases (2001) 4, 173–177 ß 2001 Nature Publishing Group All rights reserved 1365–7852/01 $15.00 www.nature.com/pcan Effects of bicalutamide and leuprolide on prostate-specific antigen (PSA), acid phosphatase (ACP) and prostatic acid phosphatase (PAP) in men with benign prostatic hyperplasia (BPH) LM Eri1* & KJ Tveter1 1Department of Urology, Ullevaal University Hospital, Oslo, Norway The effects of the nonsteroidal antiandrogen bicalutamide (CasodexTM) and the luteinizing hormone releasing hormone agonist leuprolide depot (Procren DepotTM, Lupron DepotTM) on serum prostate-specific antigen (PSA), acid phosphatase (ACP), and prostatic acid phosphatase (PAP) in patients with benign prostatic hyperplasia (BPH) were determined. Thirty patients with BPH were randomised to receive bicalutamide 50 mg orally once daily or a placebo for 24 weeks, followed by 24 weeks of follow-up (bicalutamide study). In another study 55 men were randomised between 3.75 mg leuprolide depot intramuscularly at every 28 days for 24 weeks or placebo injections (leuprolide study). In both studies blood sampling was performed at baseline, at week 12 at week 24 and 24 weeks after the end of therapy. Androgen suppression with bicalutamide 50 mg daily for 24 weeks resulted in a median of 56% reduction of PSA (P < 0.001 when compared to placebo). Acid phosphatase and PAP did not change. Leuprolide resulted in a median of 87% reduction of serum PSA (P < 0.001) and a 39% reduction of PAP (P ¼ 0.023), whereas ACP was unchanged. Both bicalutamide and leuprolide induced a pronounced decline in serum PSA in BPH patients. The studies suggest a stronger androgen suppressive effect of leuprolide than of bicalutamide, but this difference might largely be due to too low a dosage of bicalutamide.
    [Show full text]
  • An Analysis on Whether Or Not Baldness Can Be Reversed
    The Science Journal of the Lander College of Arts and Sciences Volume 10 Number 2 Spring 2017 - 2017 An Analysis on Whether or Not Baldness Can Be Reversed Spencer Waldman Touro College Follow this and additional works at: https://touroscholar.touro.edu/sjlcas Part of the Integumentary System Commons Recommended Citation Waldman, S. (2017). An Analysis on Whether or Not Baldness Can Be Reversed. The Science Journal of the Lander College of Arts and Sciences, 10(2). Retrieved from https://touroscholar.touro.edu/sjlcas/ vol10/iss2/11 This Article is brought to you for free and open access by the Lander College of Arts and Sciences at Touro Scholar. It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an authorized editor of Touro Scholar. For more information, please contact [email protected]. An Analysis on Whether or not Baldness can be Reversed Spencer Waldman Spencer Waldman will graduate with a BS in Biology in September 2017. Abstract Many men experiencing hair loss often wonder: is there a cure? Can I get my hair regrown? This thesis addresses these very issues, the anatomy of the pilosebaceous hair, the hair growth cycle, and the suggested causes of male male pattern hair loss are examined. Finally, the Various drugs that have been suggested to reduce hair loss and even cause hair regrowth are reviewed. After examining the various treatments, it can be concluded with reasonable certainty that hair loss can be halted and often reversed by using FDA approved drugs finasteride and minoxidil.
    [Show full text]
  • Versus Low-Dose Finasteride
    European Journal of Endocrinology (2002) 147 467–471 ISSN 0804-4643 CLINICAL STUDY Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism Fahri Bayram, I Ipek Mu¨derris1, Muhammed Gu¨ven and Fahrettin Keles¸timur Departments of Endocrinology and Metabolism and 1Obstetrics and Gynecology, Faculty of Medicine, Erciyes University, Kayseri, Turkey (Correspondence should be addressed to F Bayram, Department of Endocrinology and Metabolism, Medical Faculty, Erciyes University, 38039, Kayseri, Turkey; Email: [email protected]) Abstract Objective: To compare the clinical efficacy and safety of high-dose (5 mg/day) and low-dose (2.5 mg/ day) finasteride in the treatment of hirsutism in women. Design: A prospective, randomized and controlled clinical trial. Methods: Fifty-six hirsute women with moderate to severe hirsutism were prospectively evaluated to see the effects of low-dose (2.5 mg/day) and high-dose (5 mg/day) finasteride. Patients were randomly divided into two treatment groups. Group I ðn ¼ 29Þ received 2.5 mg finasteride/day and group II ðn ¼ 27Þ received 5 mg finasteride/day orally for 1 year. Hirsutism score, body mass index and hor- monal parameters (FSH, LH, estradiol, androstenedione, testosterone, free testosterone, 17a-hydroxy- progesterone, dehydroepiandrosterone sulfate and sex hormone-binding globulin) were measured in all the patients before treatment and repeated at six-monthly intervals. Results: The hirsutism scores decreased significantly at months 6 and 12 from a mean^S.D. of 18:4^ 4:6to13:3^5:2 ðP , 0:001Þ and 18:4^4:6to8:6^4:2 ðP , 0:001Þ in group I and from 18:7^5:2 to 13:9^5:3 ðP , 0:001Þ and 18:7^5:2to10:3^5:0 ðP , 0:001Þ in group II respectively.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0258972 A1 Rafi Et Al
    US 20120258972A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0258972 A1 Rafi et al. (43) Pub. Date: Oct. 11, 2012 (54) COMPOSITION AND METHODS FOR A63/496 (2006.01) TREATING HARLOSS A6IP 7/4 (2006.01) (52) U.S. Cl. .................................... 514/254.07: 514/275 (76) Inventors: Asif Rafi, Los Angeles, CA (US); Roger M. Katz, Marina Del Rey, (57) ABSTRACT CA (US) A method for treatinghair loss caused by androgenicalopecia and/or male pattern baldness. The method, which not only (21) Appl. No.: 13/440,304 slows hair loss but causes hair re-growth, includes approxi mately daily application to a subject's Scalp of a novel com (22) Filed: Apr. 5, 2012 position comprising finasteride (PropeciaR) or Proscar(R), O O dutasteride (Avodart(R), and minoxidil (RogaineR) as active Related U.S. Application Data ingredients in a hypoallergenic cream-based vehicle, prefer (60) Provisional application No. 61/472,567, filed on Apr. ably coupled with daily ingestion of 1 mg per day of finas 6, 2011. teride (PropeciaR) or Proscar R), application to the scalp of 5% minoxidil (RogaineR) foam approximately once per day, O O and use of a ketoconazole-containing shampoo (e.g., Publication Classification Nizoral R) approximately 2-3 times per week. The method (51) Int. Cl. described herein also resolves Scalp dermatitis in atopic Sub A6 IK3I/506 (2006.01) jects Suffering therefrom. A method for making the novel A6IP3I/O (2006.01) composition is also provided. US 2012/0258.972 A1 Oct. 11, 2012 COMPOSITION AND METHODS FOR which causes the hair follicles to shrink.
    [Show full text]
  • Interpretation of Serum PSA in Men Taking 5, Alpha Reductase Inhibitors
    Interpretation of Serum PSA in Men Taking 5α-Reductase Inhibitors Jonathan P. Jarow Division of Reproductive and Urologic Products CDER/FDA 1 Issue Does PSA testing provide false reassurance for men taking 5α-reductase inhibitors and, therefore, lead to a delay in diagnosis of cancer? 2 Prostate Cancer • Most common solid organ cancer in men • Second most common cause of cancer death in men (~30,000 per year) • Serum PSA in conjunction with digital rectal exam is the most effective method of early detection • European Randomized Study of Screening for Prostate Cancer reported a 20% reduction in prostate cancer mortality and a 41% reduction in metastatic disease at diagnosis in an intent-to- screen analysis conducted with a mean follow up time of 9 years 3 Prostate Specific Antigen • Glycoprotein secreted by prostatic epithelium • PSA is a serine protease responsible for liquefaction of semen • PSA production/secretion is under androgenic control • Serum PSA is indicated for screening for and monitoring prostate cancer 4 5α-Reductase Inhibitors (5-ARIs) • Finasteride 5 mg: treatment of BPH • Finasteride 1 mg: male pattern hair loss • Dutasteride 0.5 mg: treatment of BPH • PSA reduction of ~50% within 3 months 5α-Reductase Testosterone Dihydrotestosterone 5 Prostate Cancer Chemoprevention Trial Designs Dutasteride Yr 2 Yr 4 0.5 mg: Biopsy Biopsy Placebo REDUCE 4 wk 1:1 R Placebo or Dutasteride (REDUCE) Placebo A Run-In N D Placebo or Finasteride (PCPT) PCPT 3 mo. 1:1 Finasteride 5 mg: Unscheduled For-Cause Placebo Biopsy: Yr 7 Biopsy 6 Conclusions
    [Show full text]